NAFLD/NASH Clinical Development

Your CRO of Choice for NAFLD/NASH Studies

Accelerate your NAFLD/NASH study with Medpace’s noted medical and regulatory experts, highly experienced clinical trial management teams, central labs, and imaging core labs

Gain a competitive edge for your non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) study by partnering with a scientifically-driven clinical research organization that has the experience and relationships in place to get your study up and running as soon as possible. As a therapeutically-aligned CRO, Medpace has the relevant and recent gastroenterology and hepatology experience to successfully navigate the complexities and regulatory scrutiny involved with these programs. Our experience, coupled with our strong relationships with KOLs and investigative sites and our in-house central lab and imaging core lab services, set you up for long term success.

Why Choose Medpace for NAFLD/NASH Studies?

• Over eight years supporting NAFLD/NASH clinical trials
• In-house physicians, imaging specialists, and operational teams with relevant and recent successful execution of NASH studies with different endpoints including liver pathology
• Wholly-owned central lab with validated NASH soluble inflammation and fibrosis biomarkers
• Well established relationships with KOLs and high producing quality sites
• US and global experience that spans 14 countries, 1,300 subjects and 150 sites
• Wholly-owned imaging core lab to support NAFLD/NASH studies, ensuring imaging components such as MRE, MRI, PDFF, MRS and LMS are seamlessly integrated into the complex structure of the overall trial
• Established processes and relationships for central pathology assessments
• Hands-on regulatory affairs to guide you through the fastest path to commercial success

Leverage Our Therapeutic Expertise throughout the Trial Lifecycle

Our therapeutically aligned project teams serve as an extension of your team – providing additional medical, regulatory and operational expertise to your study. You benefit from:

• In-house physicians that are embedded into the study from project initiation to completion, providing hands-on leadership and translating medical knowledge into execution
• Seasoned and highly-trained operational teams with extensive experience in managing GI and hepatology studies, including recent experience in NAFLD/NASH
• Global regulatory experts, including former FDA officials, who can add input, strategy, and efficiencies based on their in-depth understanding of the local and global regulatory landscape